CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ATYR1923 1 mg/kgWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug91 ATYR1923 3 mg/kg Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)

A Phase 2 study to evaluate the safety and preliminary efficacy of ATYR1923, compared to placebo, in hospitalized patients with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation

NCT04412668 SARS-CoV-2 (COVID-19) Severe Pneumonia Drug: ATYR1923 1 mg/kg Drug: ATYR1923 3 mg/kg Drug: Placebo
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: Incidence of treatment-emergent adverse events (TEAEs)

Time: Baseline through Day 60

Secondary Outcomes

Measure: Time to normalization of oxygen saturation (SpO2) (>93% on room air sustained for at least 24 hours)

Time: Baseline through Day 14 or discharge

Measure: Duration of supplemental oxygen (O2) requirement

Time: Baseline through Day 14 or discharge

Measure: Number of days with fever (temperature >100.4ºF [38.0ºC])

Time: Baseline through Day 14 or discharge

Measure: Time to normalization of temperature (≤100.4ºF [38.0ºC])

Time: Baseline through Day 14 or discharge

Measure: Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60

Time: Baseline through Day 60

Measure: Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score

Time: Baseline through Day 60


Related HPO nodes (Using clinical trials)